Invention Permits At-Home Blood Tests
#SickleTest
Invention Permits At-Home Blood Tests
#SickleTest
Research Terms
Current methods for single-cell analysis, such as Electrical Impedance Spectroscopy (EIS) and optical tweezers, are limited to measuring either electrical or mechanical properties, not both. While EIS provides insights into electrical characteristics and optical tweezers assess mechanical attributes, neither approach can simultaneously capture both types of data. This separation results in incomplete cellular profiles and requires complex, low-throughput setups. There is a critical need for a solution that unifies these measurements to offer a comprehensive view of cellular health without the need for invasive labeling or extensive sample preparation.
Researchers at Florida Atlantic University have developed an innovative Electro-Deformation Spectroscopy (EDS) system that addresses the limitations of existing single-cell analysis methods. This technology combines electrical and mechanical measurements into a single, high-throughput platform, enabling simultaneous assessment of both properties without the need for labeling or complex setups. The EDS system utilizes a microfluidic device with embedded microelectrodes to induce electro-deformation in cells, capturing comprehensive data on cell health and function in a more efficient and accessible way. Currently, the EDS system is in the preclinical development stage, with ongoing studies to validate its effectiveness across a variety of cell types and conditions.
FAU seeks to advance this innovation into the marketplace through licensing or development partnerships.
Sickle cell disease is a genetic disorder that afflicts more than 100,000 people in the United States, with hospitalization costs exceeding $1.1 billion annually. Early diagnosis and close monitoring of sickle cell activity are essential for the successful treatment of this condition. However, standard diagnosis requires expensive laboratory equipment, reagents and adequately trained laboratory personnel. New point-of-care diagnostics are needed to improve the treatment outcomes of this devastating disease.
Researchers at Florida Atlantic University have developed a novel finger-prick diagnosis and monitoring platform enabling quick, accurate, and inexpensive diagnosis of sickle cell disease and functional measurement of sickle cell blood. The technology can evaluate small sample volumes acquired via a finger prick. A prototype of the device has been developed and has analyzed blood samples from multiple sickle cell patients. Preliminary data showed the technology accurately diagnoses the condition with similar accuracy to FDA-approved products.
FAU seeks partners to advance this technology into the marketplace through licensing or development partnerships.
Sickle Cell Disease (SCD) poses a substantial healthcare challenge, particularly due to its prevalence and the high cost of care. Traditional diagnostic methods are cumbersome, require significant time, and depend on centralized laboratories, which hinders timely and efficient patient management.
Researchers at Florida Atlantic University have developed a breakthrough micro impedance device (μZAS) that represents a significant leap in SCD diagnostics. The device enables rapid, accurate measurement of sickle cell properties directly from whole blood. By providing real-time results at the point of care, it greatly simplifies the monitoring and management process for SCD. This not only enhances patient care but also promises to substantially reduce healthcare costs.
FAU seeks to advance this innovation into the marketplace through licensing or development partnerships.
Sickle cell disease is a genetic disorder that afflicts more than 100,000 people in the United States, with hospitalization costs exceeding $1.1 billion annually. Early diagnosis and close monitoring of sickle cell activity are essential for the successful treatment of this condition. However, standard diagnosis requires expensive laboratory equipment, reagents and adequately trained laboratory personnel. New point-of-care diagnostics are needed to improve the treatment outcomes of this devastating disease.
Researchers at Florida Atlantic University have developed a novel finger-prick diagnosis and monitoring platform enabling quick, accurate, and inexpensive diagnosis of sickle cell disease and functional measurement of sickle cell blood. The technology can evaluate small sample volumes acquired via a finger prick. A prototype of the device has been developed and has analyzed blood samples from multiple sickle cell patients. Preliminary data showed the technology accurately diagnoses the condition with similar accuracy to FDA-approved products.
FAU seeks partners to advance this technology into the marketplace through licensing or development partnerships.
